Page 71 - Read Online

Lee et al. Hepatoma Res 2020;6:21 I http://dx.doi.org/10.20517/2394-5079.2019.44 Page 7 of 8

45. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for
HCV in patients with cirrhosis Included in surveillance programs. Gastroenterology 2018;155:1436-50.
46. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, et al.; Kyushu University Liver Disease Study (KULDS) Group. Short-term
risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol
Ther 2018;47:104-13.
47. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, et al. Increased risk for hepatocellular carcinoma persists up to 10 years
after HCV eradication in patients with baseline cirrhosis or high FIB-4 Scores. Gastroenterology 2019;157:1264-78.
48. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct
acting antiviral agents. Hepatology 2020;71:44-55.
49. Llovet JM, Villanueva A. Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol
Hepatol 2016;13:561-2.
50. Reig M, Boix L, Mariño Z, Torres F, Forns X, et al. Liver cancer emergence associated with antiviral treatment: an immune
surveillance failure? Semin Liver Dis 2017;37:109-18.
51. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, et al. Levels of cytokines in serum associate
with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology
2018;154:515-7.e3.
52. Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral
agents. Viruses 2019;11:406.
53. Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after direct-acting antiviral therapy. Int J
Mol Sci 2019;20:49.
54. Singal AK, Freeman DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular
carcinoma. Aliment Pharmacol Ther 2010;32:851-8.
55. Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, et al. Impact of direct-acting antivirals on early recurrence of
HCV-related HCC: comparison with interferon-based therapy. J Hepatol 2019;70:78-86.
56. Colombo M, Boccaccio V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat Rev Gastroenterol Hepatol 2018;15:392-3.
57. Reig M, Boix L, Bruix J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver
Int 2017;37:136-9.
58. Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral
treatment for hepatitis C virus infection: literature review and risk analysis. Dig Liver Dis 2018;50:1105-14.
59. Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, et al. Direct-acting antivirals and hepatocellular carcinoma in chronic
hepatitis C: a few lights and many shadows. World J Gastroenterol 2018;24: 2582-95.
60. Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, et al. Systematic review with meta-analysis: recurrence of hepatocellular
carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther 2018;48:127-37.
61. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of
hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.
62. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, et al. Cure with interferon free DAA is associated with increased survival in patients
with HCV related HCC from both East and West. Hepatology 2019; Epub ahead of print [PMID: 31610027 DOI: 10.1002/hep.30988]
63. Saberi B, Dadabhai AS, Durand CM, Philosophe B, Cameron AM, et al. Challenges in treatment of hepatitis C among patients with
hepatocellular carcinoma. Hepatology 2017;66:661-3.
64. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran
patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
65. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, et al. Hepatocellular carcinoma decreases the chance of
successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017;66:1173-81.
66. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, et al. Real-world experience with interferon -free, direct-acting antiial therapies in
Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) 2017;96:e6128.
67. Soria A, Fabbiani M, Lapadula G, Gori A. Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with
hepatocellular carcinoma during treatment with direct-acting antivirals. Hepatology 2017;66:992-4.
68. Ji F, Yeo YH, Wei MT, Wei B, Dang S, et al. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment:
do direct-acting antiviral regimens matter? Hepatology 2018;67:1180-2.
69. Harrod E, Moctezuma-Velazquez C, Gurakar A, Ala A, Dieterich D, et al. Management of concomitant hepatocellular carcinoma and
chronic hepatitis C: a review. Hepatoma Res 2019;5:28.
70. Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, et al. Treatment of patients waitlisted for liver transplant with all-
oral direct-acting antivirals is a cost-effective treatment strategy in the United Status. Hepatology 2017;66:46-56.
71. Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, et al. Treatment status of hepatocellular carcinoma does not
influence rates of sustained virologic response: an HCV-TARGET analysis. Hepatol Commun 2019 ;3:1388-99.
72. Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver
Int 2018;38:139-45.
73. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, et al. European liver and intestine association (ELITA).
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524-31.
74. Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, et al. Use of direct-acting antiviral agents in hepatitis C virus-
infected liver transplant candidates. World J Gastroenterol 2018;24:315-22.
75. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, et al. Clinical outcomes of patients undergoing antiviral therapy while
awaiting liver transplantation. J Hepatol 2017;67:1168-76.